baber/WOPTO huggingface dataset:
Patent AU-733079-B2 (AU)
Title: Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses
Inventor: TARTAGLIA JAMES
IPC: A61K39/00
Filed: 1997-11-07
Granted: 2001-05-03
Abstract: Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodeficiency virus epitope such as an antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinants can be NYVAC or ALVAC recombinants. The DNA can encode at least one of: Env, Gag, Pol, or combinations thereof such as Gag and Pol or protease or Env, Gag and Pol or protease. The recombinants and gene products therefrom and antibodies generated by them have several preventive, therapeutic and diagnostic uses. DNA from the recombinants are useful as probes or, for generating PCR primers or for immunization. The immunogenicity and protective efficacy of immunization protocols involving ALVAC-FIV and priming with a recombinant canarypox virus ALVAC-FIV vaccine followed by a booster immunization with inactivated FIV-infected celled vaccine (ICV) was evaluated against FIV challenge in cats and the protocol was shown to effectively induce FIV-specific protective immune responses. Further, it was found that immunized cats were fully protected from an initial challenge with a slightly heterologous FIV strain (50CID<SUB>50</SUB>) and were partially protected from a second challenge with a distinctly heterologous FIV strain (75CID<SUB>50</SUB>) given eight months after the initial challenge without any intervening booster.
Patent AU-668239-B2 (AU)
Title: Nonatetraenoic acid derivative
Inventor: DORAN THOMAS I
IPC: C07C69/734
Filed: 1993-12-15
Granted: 1996-04-26
Abstract: A compound of the formula <CHEM> its pharmaceutically acceptable salts, and its pharmaceutically acceptable hydrolyzable esters for reducing sebum secretion and combatting acne as well as oral and topical compositions for use thereof.
Patent AU-727142-B2 (AU)
Title: Invisible fluorescent Jetink
Inventor: ZHU LINFANG
IPC: C09D11/00
Filed: 1997-12-10
Granted: 2000-12-07
Abstract: Disclosed is a jet ink composition suitable for printing marks on metal, glass, plastics, rubber, or paper comprising an ink carrier, a fluorescent colorant, a cellulosic binder resin, and a tetraalkyl ammonium or phosphonium salt. The jet printed marks do not blush, bleed, or fade, as a result of exposure to steam, or hot and cold water. Also disclosed is an improved process of jet printing on substrates comprising printing with the disclosed jet ink composition.\!
Patent AU-686578-B2 (AU)
Title: Lactone compound and process of production thereof
Inventor: TABE MASAYASU
IPC: C07C401/00
Filed: 1994-02-02
Granted: 1998-02-12
Abstract: A lactone compound, useful as an osteogenetic accelerator, having the formula (I): <CHEM> wherein n is zero or 1 and m is zero or 1, provided that both n and m are not zero at the same time, or a stereoisomer thereof at the 23- and/or 25-positions or any mixture thereof and a production process thereof.
Patent AU-749963-B2 (AU)
Title: Process and catalyst for making dialkyl carbonates
Inventor: RYU J YONG
IPC: C07C68/00
Filed: 1999-08-10
Granted: 2002-07-04
Abstract: A process for producing dialkyl carbonates, such as dimethyl carbonate, from the reaction of a primary alcohol with urea in the presence of a novel organotin catalyst complex with a high boiling electron donor compound acting as solvent which are <DEL-S DATE="20010821" ID="DEL-S-00001">(1) materials having the general formula RO[CH2(CH2)kCH2O]mR, wherein each R is independently selected from C1-12 alkyl, alkaryl or aralkyl moieties, k=0,1, 2 or 3 and m=1, 2, 3, 4 or 5 and (2)<DEL-E ID="DEL-S-00001">  bidentate ligand which form 1:1 bidentate and/or 1:2 monodentate adducts with R'2SnX2(X=Cl, R'O, R'COO or R'COS), R'3SnX, R'SnO, Ph3-nR'SnXn or Ph4-nSnXn (wherein R'=CqH2q-1n=0, 1 or 2 and q=<DEL-S DATE="20010821" ID="DEL-S-00002">2<DEL-E ID="DEL-S-00002">  <INS-S DATE="20010821" ID="INS-S-00001">1 <INS-E ID="INS-S-00001">to 12) and mixtures thereof<INS-S DATE="20010821" ID="INS-S-00002">, such as materials having the general formula RO[CH2(CH2)xCH2O]mR, wherein each R is independently selected from C1-12 alkyl, alkaryl or aralkyl moieties, k=0,1, 2 or 3 and m=1, 2, 3, 4, or 5<INS-E ID="INS-S-00002">.
Patent AU-716404-B2 (AU)
Title: Stabilised vinyl chloride polymer compositions
Inventor: HARVEY HEATHER BLUE
IPC: C08K5/13
Filed: 1996-05-15
Granted: 2000-02-24
Abstract: PCT No. PCT/GB96/01156 Sec. 371 Date Feb. 25, 1998 Sec. 102(e) Date Feb. 25, 1998 PCT Filed May 15, 1996 PCT Pub. No. WO96/36663 PCT Pub. Date Nov. 21, 1996The present invention relates to a composition based on polymer and/or co-polymers of vinyl chloride including organotin salts and/or one or more divalent metal salts of a carboxylic acid or phenol, and one or more metal salts of the organic compounds of general formula A: in which R1 represents a linear or branched alkylene or alkenylene radical having up to 20 carbon atoms, an aralkylene radical having from 7 to 20 carbon atoms or an arylene or cycloalkylene radical having from 6 to 20 carbon atoms, the cycloalkylene radicals optionally containing carbon-carbon double bonds; these radicals optionally being unsubstituted or substituted for example by one or more or halogen atoms or hydroxyl groups or, for aryl or cycloalkylene radicals, by one or more methyl, ethyl or methoxy radicals, the above-mentioned radicals optionally modified by the presence in an aliphatic chain of one or more -O-, -CO- or CO2 -chain members or N; R2 represents O,S,NR5 or NNHR5 wherein R5 is defined as R1, H or C(S)NHR6 wherein R6 is defined as R1 or H; R3 and R4 are defined as R1 or H and can be the same or different; A is either, O, S or NR7, with R7 defined as R1 and H, with the exception that when A =O, R2=+544 =O.
Patent AU-535196-B2 (AU)
Title: Separating rare earth ozides from galliom oxide
Inventor: LEVEQUE ALAIN
IPC: C22B3/00
Filed: 1980-07-01
Granted: 1984-03-08
Abstract: 1. Process for the treatment of a mixture of rare earth oxides and gallium oxides, characterized in that, in a first step, the mixture is dissolved by means of an acid, in a second step, the solution resulting from the acid attack is brought into contact with an organic phase containing at least one water-insoluble extraction agent, optionally dissolved in a diluent and chosen from amongst the class of the anionic extraction agents, the classes of the solvating extraction agents or the class of the cationic extraction agents, so as to seperate the gallium from the rare earths by liquid-liquid extraction, and in a third step, after the said extraction, the gallium is recovered in the organic phase and the rare earths in the aqueous phase, or the gallium is recovered in the aqueous phase and the rare earths in the organic phase.
Patent AU-626714-B2 (AU)
Title: Process for the removal of cholesterol or cholesterol esters from foodstuffs
Inventor: CULLY JAN DR
IPC: A23L5/20
Filed: 1990-08-27
Granted: 1992-08-06
Abstract: The present invention provides a process for the removal of cholesterol and/or cholesterol esters from foodstuffs by extraction with compressed carbon dioxide, wherein a) the cholesterol-containing extraction material is treated with compressed carbon dioxide at a pressure above 100 bar and at a temperature of from 10 DEG  to 90 DEG C., b) from the carbon dioxide stream loaded with cholesterol and/or cholesterol esters, as well as with further lipophilic components, the cholesterol components are selectively removed by adsorption on a solid adsorption agent or by adduct formation and c) at least a part of the carbon dioxide current substantially free from cholesterol components is again passed over the treated extraction material and/or used for the extraction of untreated, cholesterol-containing extraction material.
Patent AU-586594-B2 (AU)
Title: Dual mode I.V. infusion device with distal sensor
Inventor: BLOOMQUIST TED C
IPC: A61M5/142
Filed: 1986-10-29
Granted: 1989-07-13
Abstract: An improved dual mode peristaltic device (22) is provided for infusing I.V. solutions to a patient through an I.V. tube (16). In a first mode of operation, the device functions as a peristaltic pump and in the second mode of operation it functions like a controller. Included in the device (22) and associated with the I.V. tube (16) is a pressure sensing strain gauge assembly (44) that monitors dimensional changes in the outer diameter of the I.V. tube (16) as an indication of fluid pressure changes in the tube (16). The strain gauge assembly (44) is positioned relative to the device's peristaltic means (42) to alternately monitor fluid pressure in a patent I.V. tube (16) upstream and downstream from the gauge assembly (44). A pair of stationary fingers surround the strain gauge assembly (44) to isolate it from the pulsitile nature of the peristaltic action of the device (22). In the first mode (pump mode), the device (22) is programmed to alarm and cease operation when fluid pressure downstream from the gauge assembly (44) reaches a preselected value. In the second mode (controller mode), the device (22) is programmed to alarm and cease operation when there is no differential between fluid pressure upstream and downstream from the gauge assembly (44).
Patent AU-640173-B2 (AU)
Title: Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias
IPC: A61K38/20
Filed: 1990-10-17
Granted: 1993-08-19
Abstract: The invention relates to the use of a polypeptide having human interleukin-2 activity for preparing a pharmaceutical composition intended for the treatment of leukaemias. Polypeptide having human IL-2 activity is understood to mean natural human IL-2 or recombinant human IL-2, that is to say obtained by recombinant DNA technology. The leukaemias to which the invention relates comprise chronic myeloid or chronic lymphoid leukaemias and acute lymphoid or non-lymphoblastic leukaemias, for example myeloid leukaemias characterised in a general manner by the proliferation of blast cells.
Patent AU-690110-B2 (AU)
Title: Use of steroid antagonists for the therapy and prophylaxis of demential illnesses
Inventor: DENECKE RAINER
IPC: A61K31/135
Filed: 1994-03-30
Granted: 1998-04-23
Abstract: Compsns. for therapy and prophylaxis of dementia disorders, esp. associated with diminishing cellular activity, contain steroid antagonists (I) or steroid agonists (II). (I) are receptor-specific pure antagonists, receptor-nonspecific partial agonists or steroid antagonists metabolites. (II) are receptor-specific pure agonists, receptor-nonspecific partial antagonists or steroid agonist metabolites. In both cases, the steroid in question is an androgen, oestrogen or progesterone.
Patent AU-582529-B2 (AU)
Title: Method and means for parking read/write heads in a disc drive using the back-EMF of the spindle motor to operate a stepper moter
Inventor: WEVERS WILLIAM E
IPC: G11B19/20
Filed: 1986-11-19
Granted: 1989-03-23
Abstract: Electronic circuitry is provided to position the read/write heads (10) in a designated landing zone when the electrical power is removed from the drive (27). when power is removed from the drive, the stored energy of the rotating spindle motor (27) is used as a source of electrical power and timing pulses to the stepper motor (30) which drives the actuator of the disc drive. The power generated by the spindle motor as it spins down is referred to as "back EMF". A sequencer circuit (50) is provided to couple the power and clock pulses to selected windings of the stepper motor (30) in an order that will cause the stepper motor to rotate in the direction necessary to move the transducer heads (10) to a predetermined park position at the inner diameter of the disc whenever power is removed from the disc drive. Since the location of the heads at power down may not be known, the timing of the pulses in such that a sufficient number of steps will be taken to move the transducer heads to the parking zone within the time allotted even if power down occurred when the heads were at the outermost track. Step pulses will continue to be generated until the back EMF of the spindle motor is insufficient to generate such pulses. After the transducer heads are at the predetermined parking location, any additional steps will cause the actuator to contact a mechanical "inner crash stop" designed to prevent damage to the transducer heads from contact with the clamp which retains the discs.
Patent AU-736709-B2 (AU)
Title: Isolation of hemicellulose from corn fiber
Inventor: DONER LANDIS W
IPC: C08B37/14
Filed: 1998-03-13
Granted: 2001-08-02
Abstract: This invention pertains to a high yield process for producing high quality corn fiber gum by hydrogen peroxide treatment of corn fiber during alkaline extraction and/or after obtaining the alkaline extract of milled corn fiber. This process comprises the steps: a) mixing corn fiber with an alkaline solution to form a slurry and extract hemicellulose; b) treating the slurry with hydrogen peroxide at a pH of about 10.0 to 12.5; and c) separating out the insoluble fractions from the corn fiber slurry to yield corn fiber gum. The corn fiber gum produced by this process is highly soluble in water and provides low viscosity solutions which are nearly devoid of color over a wide pH range. The corn fiber gum lacks objectionable flavor and aroma. The corn fiber gum is useful for a variety of applications, including film formation and to thicken, emulsify, stabilize and/or extend aqueous solutions and suspensions.
Patent AU-675534-B2 (AU)
Title: Multiple medication injection apparatus and method
Inventor: PAWELKA GERHARD E F
IPC: A61M5/19
Filed: 1994-04-01
Granted: 1997-02-06
Abstract: A hand-held dual liquid medication injector have dual, bi-directional dosage metering mechanisms for permitting a variable dosage amount for each cartridge of liquid medication. The medications are mixed within a manifold having a valved mixing chamber and are injected via a single cannula. The mixing chamber is valved such that backflow of mixed or unmixed medications into the cartridges is prevented. An injection mechanism, independent of the metering mechanism, loads and injects the liquid medication. In one embodiment, downward movement of the injection mechanism during injection is translated into horizontal movement by the plunger mechanism. In another embodiment, a power-assisted plunger mechanism accomplishes injection.
Patent AU-690859-B2 (AU)
Title: Stent delivery device and method for manufacturing a stent delivery device
Inventor: LUKIC GORAN
IPC: A61F2/06
Filed: 1996-10-14
Granted: 1998-04-30
Abstract: The stent delivery device comprises an elongated sheath (2) with a self-expandable stent (7) placed in contracted condition within the distal area (3) of the sheath (2). An elongated core (5) is arranged in the sheath (2) for relative longitudinal motion between core and sheath, and drive means (13) are arranged between the core (5) and the stent (7). Scratch protection tubular means (16) comprise a reinforcement ring (18) secured in the sheath (2) and surrounding the distal end portion (79) of the stent when the stent is in contracted condition in the sheath and a tube of thermoformable material (37) heat shrunk over the proximal end portion (78) of the stent and over the core (5). <IMAGE>
Patent AU-601966-B2 (AU)
Title: Compositions suitable in or as film, coating mastic, adhesive, caulk compositions, and a method of making them
Inventor: CHIOU SHANG-JAW
IPC: C09D133/00
Filed: 1987-03-04
Granted: 1990-09-27
Abstract: A composition comprises a solution of film forming polymer, containing reactive functionality, dissolved in organic solvent and insoluble reinforcing particles dispersed therein. The reinforcing particles, being formed in the presence of the film forming polymer, are the reaction product of a system comprising (a) polyethylenically unsaturated monomer, (b) a portion of said film-forming polymer and, when said reactive functionality is other than ethylenic unsaturation, (c) a linking monomer which contains both ethylenic unsaturation and a group reactive with said reactive functionality. The composition has use in or as a film, coating mastic, adhesive or caulk composition.
Patent AU-774801-B2 (AU)
Title: Low-dose tablets and preparation method
Inventor: COUARRAZE GUY
IPC: A61K9/50
Filed: 2000-07-25
Granted: 2004-07-08
Abstract: The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste.
Patent AU-720063-B2 (AU)
Title: Apparatus and method for controlling molecular cluster in fluid
Inventor: IBBOTT JACK KENNETH
IPC: C02F1/48
Filed: 1996-10-28
Granted: 2000-05-25
Abstract: An apparatus provides for controlling molecular clusters in fluid in which an electric or a magnetic energy field is applied to a fluid transversely to the flow direction thereof passing through a pipe means. The width of the energy field parallel to the direction of the fluid flow is less than 1 millimeter. The energy field may be applied by two electrodes or two magnetic ploes in which the overall thickness of the electrodes or magnetic poles is less than 10 millimeters. The electrodes or magnetic poles are preferably provided on the outer peripheral surface of the pipe means.
Patent AU-646842-B2 (AU)
Title: Lipid-free polysaccharide compound, preparation process, compositions containing it
Inventor: BINZ HANS
IPC: C07K14/26
Filed: 1991-03-06
Granted: 1994-03-10
Abstract: Polysaccharide D 25 compound partially delipidated and its derivatives, characterised in that at least 85 % by weight, preferably 90 %, of the compound is in aqueous solution in monomeric form. Reference is made in particular to the polysaccharide compound of molecular weight 30 kD extracted from membrane proteoglycan of the bacteria Klebsiella pneumoniae. The content of palmitic fatty acids which are bonded to it in esterified form does not excees 0.01 % by weight of the compound and the content of palmitic fatty acids which are associated with it in free form does not exceed 0.1 % by weight of the compound.
Patent AU-635118-B2 (AU)
Title: 2-(substituted pyrrolidinylthio)carbapenem derivatives
IPC: C07D477/20
Filed: 1991-03-25
Granted: 1993-03-11
Abstract: A compound of the formula: <CHEM> wherein R is a hydrogen atom or a methyl group, R<1> is a hydrogen atom or a negative charge, each of R<2> and R<3> which may be the same or different, is a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a formimidoyl group, an acetoimidoyl group, -COOR<4>, -CON(R<5>)R<6>, -N(R<5>)R<6>, -CH2COOR<4>, -CH2N(R<5>)R<6> or -CH2CON(R<5>)R<6> (wherein R<4> is a hydrogen atom or a lower alkyl group, each of R<5> and R<6> which may be the same or different, is a hydrogen atom or a lower alkyl group, or R<5> and R<6> form together with the adjacent nitrogen atom a heterocyclic group selected from the group consisting of an aziridinyl group, an azetidinyl group, a pyrrolidinyl group and a piperidyl group), A is =NR<7>, =N/<+>(R<7>)R<8>, -CON(R<7>)-, -CON(R<7>)CO-, -CON(R<7>)CON(R<8>)-, -N(R<7>)CO(CH2)sN(R<8>)-, -N(R<7>)CO(CH2)sCON(R<8>)-, -CON(R<7>)N(R<8>)- or -N(R<7>)(CH2)sN(R<8>)- {wherein each of R<7> and R<8> which may be the same or different, is a hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group, a formimidoyl group, an acetoimidoyl group, -COOR<4>, -CON(R<5>)R<6>, -N(R<5>)R<6>, -CH2COOR<4>, -CH2N(R<5>)R<6> or -CH2CON(R<5>)R<6> (wherein R<4>, R<5> and R<6> are as defined above), s is an integer of from 1 to 3}, p is an integer of from 0 to 3, and each of q and r which may be the same or different, is an integer of from 0 to 5, provided that q and r are not simultaneously 0 and q + r </= 6; or a pharmaceutically acceptable salt or ester thereof.
Patent AU-639549-B2 (AU)
Title: Parasiticidal composition and methods for its making and use
IPC: A01N53/00
Filed: 1991-02-28
Granted: 1993-07-29
Abstract: A liquid phase composition of a pyrethroid in concentrations greater than 50% w/w that may be used as a basis for other pyrethroid containing formulations in physical phases other than the liquid phase is described. A method of treatment utilizing the composition on domestic mammal is also described. The composition can be applied as a small dose to a localized region of the animal's body which is then delivered to relatively all of the animal's body surface by migration of the pyrethroid.
Patent AU-654947-B2 (AU)
Title: Non-invasive method of and equipment for determining kinematic movement of the cervical spine
Inventor: FUHR ARLAN W
IPC: A61B5/11
Filed: 1991-03-18
Granted: 1994-12-01
Abstract: A non-invasive method and equipment for determining kinematic movement of the cervical spine. The method compares biomechanical pathways of a human patient's head's free range of motion in space with either standardized biomechanical pathway data or priorly determined biomechanical pathway data of the same person, to determine the nature and extent of abnormal kinematic movement.
Patent AU-775508-B2 (AU)
Title: Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
Inventor: WEI EDWARD T
IPC: A61K38/22
Filed: 2000-09-19
Granted: 2004-08-05
Abstract: The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly lower blood pressure but have anti-proliferative actions in cell culture and inhibit experimental cancer growth in animals (mice and rats). Novel applications of such analogs are described, such as to inhibit abnormal cell proliferation for conditions such as cancer, including melanoma, and for inflammatory dermatoses, such as psoriasis.
Patent AU-680555-B2 (AU)
Title: Process for manufacture of reduced fat and reduced calorie chocolate
Inventor: ZUMBE ALBERT
IPC: A23G1/20
Filed: 1994-10-17
Granted: 1997-07-31
Abstract: PCT No. PCT/GB94/02265 Sec. 371 Date Jul. 9, 1996 Sec. 102(e) Date Jul. 9, 1996 PCT Filed Oct. 17, 1994 PCT Pub. No. WO95/10946 PCT Pub. Date Apr. 27, 1995A process is provided for producing a chocolate composition reduced in fat and calories, which either contains sugar or is free of added sugar, and which has the taste and mouthfeel of traditional chocolate. The process involves developing the chocolate flavour during a normal chocolate-making procedure up to and including conching, and then removing some of the fat, e.g. by means of a cocoa liquor press.
Patent AU-646049-B2 (AU)
Title: Insect catching apparatus
Inventor: EDWARDS DAVID LAURANCE
IPC: A01M1/10
Filed: 1991-05-17
Granted: 1994-02-03
Abstract: PCT No. PCT/GB91/00778 Sec. 371 Date Dec. 28, 1992 Sec. 102(e) Date Dec. 28, 1992 PCT Filed May 17, 1991 PCT Pub. No. WO91/17654 PCT Pub. Date Nov. 28, 1991.An apparatus for catching insects is disclosed, which includes an insect-carrying chamber having an opening large enough to allow an insect to pass therethrough. The opening is closable by way of a shutter so that when the insect enters the chamber, it may be trapped therein by moving the shutter to its closed position.